EUVIMEDEUVIMED entdecken
Metaanalyse

Diagnostic Accuracy of Immunohistochemistry Testing on Sebaceous Gland Neoplasms for Muir‐Torre Syndrome: A Meta‐Analysis

Jack Hulse, Allison Swanson, Emily O'Donnell, Garth Fraga iD

Journal of Cutaneous Pathology · 2026

DOI: 10.1111/cup.70026 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Cutaneous Pathology, 2026. Verfasst von Jack Hulse und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Missouri-Kansas City, Kansas City, USA. Hauptthemen laut MEDLINE: Muir-Torre Syndrome, Sebaceous Gland Neoplasms, Immunohistochemistry. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Muir‐Torre syndrome (MTS) is a hereditary tumor predisposition syndrome associated with sebaceous neoplasms. Immunohistochemistry (IHC) for loss of mismatch repair (MMR) proteins in these tumors is used as a screening test, but its diagnostic accuracy has not been rigorously assessed.

Methods

We conducted a meta‐analysis of 25 studies involving 692 patients who underwent IHC testing for MMR protein loss in sebaceous neoplasms.

Results

The pooled sensitivity was 0.84 (95% CI: 0.75–0.90) and specificity was 0.46 (95% CI: 0.28–0.66), with significant inter‐study heterogeneity in specificity ( I 2 , 77%). Restricting the meta‐analysis to more rigorous studies with exposure‐based designs and germline mutation as the reference standard yielded higher sensitivity (0.91; 95% CI: 0.83–0.96) and lower specificity (0.14; 95% CI: 0.06–0.27). Hypothetically restricting testing to patients under 60 years or tumors outside the head/neck locations increased specificity (0.87 and 0.88, respectively) but reduced sensitivity (0.60 and 0.37, respectively). A two‐antibody panel (MSH6 and PMS2) performed equivalently to a four‐antibody panel (MLH1, MSH2, MSH6, and PMS2).

Conclusions

IHC testing can discriminate between sporadic and MTS‐associated sebaceous neoplasms, but diagnostic utility is limited by low specificity. Most MMR‐deficient cases are not due to MTS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muir-Torre SyndromeSebaceous Gland NeoplasmsImmunohistochemistryHumansDNA Mismatch RepairSensitivity and SpecificityBiomarkers, Tumor

Stichwörter der Autor:innen

DNA mismatch repairMuir‐Torre syndromegenetic predisposition to diseaseimmunohistochemistrysebaceous gland neoplasms

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • School of Medicine, University of Missouri-Kansas City, Kansas City, USA.

ORCID-Profile: Garth Fraga

Zitieren

APA

Hulse, J., Swanson, A., O'Donnell, E., & Fraga, G. (2026). Diagnostic Accuracy of Immunohistochemistry Testing on Sebaceous Gland Neoplasms for Muir‐Torre Syndrome: A Meta‐Analysis. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70026

Vancouver

Hulse J, Swanson A, O'Donnell E, Fraga G. Diagnostic Accuracy of Immunohistochemistry Testing on Sebaceous Gland Neoplasms for Muir‐Torre Syndrome: A Meta‐Analysis. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70026

BibTeX
@article{Hulse2026,
  author = {Hulse, Jack and Swanson, Allison and O'Donnell, Emily and Fraga, Garth},
  title = {Diagnostic Accuracy of Immunohistochemistry Testing on Sebaceous Gland Neoplasms for Muir‐Torre Syndrome: A Meta‐Analysis},
  journal = {Journal of Cutaneous Pathology},
  year = {2026},
  doi = {10.1111/cup.70026}
}
Kostenlos starten →